Periprosthetic osteolysis = bone loss from wear particle-induced inflammation. Detected on radiographs as radiolucencies, cystic defects; CT useful for mapping, MRI (MARS) for soft tissue. Must exclude infection before labeling aseptic osteolysis. Management: debridement of granuloma, bone grafting, bearing exchange, revision arthroplasty if components loose. Prevention: use of HXLPE, ceramics, optimal component position.
What is a common radiographic appearance of periprosthetic osteolysis?
Before labeling osteolysis as aseptic, which condition must be excluded?
Which of the following is NOT a management option for periprosthetic osteolysis?
Which stage of periprosthetic osteolysis is characterized by the presence of significant radiolucencies without implant loosening?
What is the role of MRI with MARS sequences in the evaluation of periprosthetic osteolysis?
What is the primary preventive measure to reduce the risk of periprosthetic osteolysis?
During the wear particle-osteolysis cascade, which cytokine is primarily involved in the activation of osteoclasts?
What is the significance of identifying a radiolucent line greater than 2mm on radiographs in the context of periprosthetic osteolysis?
What is the primary mechanism driving periprosthetic osteolysis?
Which imaging modality is considered the gold standard for detecting and quantifying periprosthetic osteolysis?
